PureTech Health plc (PRTC) P/E Ratio History
Historical price-to-earnings valuation from 2020 to 2024
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of March 1, 2026, PureTech Health plc (PRTC) trades at a price-to-earnings ratio of 8.4x, with a stock price of $16.77 and trailing twelve-month earnings per share of $-1.31.
The current P/E is 53% below its 5-year average of 17.9x. Over the past five years, PRTC's P/E has ranged from a low of 5.9x to a high of 35.2x, placing the current valuation at the 50th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, PRTC trades at a 65% discount to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
Relative to the broader market, PRTC trades at a notable discount to the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our PRTC DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Drug Discovery and Antibody Platforms peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
REGNRegeneron Pharmaceuticals, Inc. | $108B | 18.8 | 2.98Best | +8% |
CTMXCytomX Therapeutics, Inc. | $430M | 14.1 | - | - |
PRTCPureTech Health plc | $405M | 8.4Lowest | - | +183%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2024 Q4 | $18.46 | $0.80 | 23.1x | +29% | |
| FY2021 Q4 | Fri Dec 31 2021 00:00:00 GM | $37.00 | $1.05 | 35.2x | +97% |
| FY2021 Q2 | Wed Jun 30 2021 00:00:00 GM | $49.00 | $6.60 | 7.4x | -59% |
| FY2020 Q4 | $54.00 | $9.20 | 5.9x | -67% |
Average P/E for displayed period: 17.9x
See PRTC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PRTC Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare PRTC vs AGIO
See how PRTC stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is PRTC stock overvalued or undervalued?
PRTC trades at 8.4x P/E, below its 5-year average of 17.9x. At the 50th percentile of historical range, the stock is priced at a discount to its own history.
How does PRTC's valuation compare to peers?
PureTech Health plc P/E of 8.4x compares to sector median of 23.7x. The discount suggests lower growth expectations or higher risk.
What is PRTC's PEG ratio?
PRTC PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2020-2024.